EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSCLAG00000009454
Gene Symbol: PIK3R3
3 Cross references
276 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSCLAG00000008429
Gene Symbol: PIK3R5
3 Cross references
256 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSCLAG00000011020
Gene Symbol: PLA2G2A
2 Cross references
168 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSCLAG00000015123
Gene Symbol: PLA2G5
2 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSCLAG00000010984
Gene Symbol: PLA2G7
2 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSCLAG00000013831
Gene Symbol: PLA2G10
2 Cross references
250 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSCLAG00000012152
Gene Symbol: GART
2 Cross references
247 Possible Orthologues:

Plasminogen

Ensembl ID : ENSCLAG00000002399
Gene Symbol: PLG
2 Cross references
269 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSCLAG00000000644
Gene Symbol: PLAT
2 Cross references
203 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSCLAG00000017842
Gene Symbol: PTAFR
2 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSCLAG00000005250
Gene Symbol: PDGFRA
2 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSCLAG00000009688
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).